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Background: Genetic polymorphisms are commonly associated with altered transcriptional activity and possibly 
make individuals more susceptible to periodontal disease development, increased disease severity and poor treat-
ment outcome. The study aimed to determine the effect of Interleukin-6 (IL-6) -572 G/C (rs1800796) and IL-10 
-592 C/A (rs1800872) polymorphisms on the outcomes of non-surgical periodontal therapy in a Caucasian popula-
tion.
Material and Methods: Sixty-eight patients with chronic periodontal disease were grouped according to their 
genotype: IL-6, IL-10, IL-6 and IL-10 susceptible (SCP) and non-susceptible (NSCP). All individuals were clini-
cally evaluated at the first visit, and blood sample were collected from patients after checking the inclusion and 
exclusion criteria of the study. All patients received non-surgical periodontal therapy from a single-blinded perio-
dontist. Clinical periodontal measurements were repeated 45 days after therapy. 
Results: This population mean aged 47.63 years included 52.2% females and 58.2% non-smokers. Following DNA 
separation and genotyping, 65.7% of patients were homozygous carriers of the IL-6 - 572G; 49.3% were carriers of 
the IL-10 -592A- allele (AA and CA genotypes); and 35.8% carried SCP genotypes for both polymorphisms. The 
clinical parameters after therapy were not associated with the genotype status. The multiple logistic regression 
analysis did not show any statistically significant association between the genotypes and the variables tested. 
Conclusions: Within the limitations of this longitudinal study, it can be suggested that IL-6 -572 G/C and IL-10 
-592 C/A polymorphisms as well as their combination do not influence the outcome of nonsurgical periodontal 
therapy in Caucasian patients diagnosed with chronic periodontal disease.
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Introduction
Periodontal disease is defined as a multifactorial in-
flammatory disease that is marked by destruction of the 
supporting tissues around teeth including periodontal 
ligament, cementum, alveolar bone and it is the major 
cause of tooth loss if left untreated (1). The role of mi-
crobial plaque in the onset of periodontal disease is pri-
mary and it results from interaction between host and 
microbial factors. Although there are some risk factors 
of periodontal disease that can be modified including 
smoking, diabetes mellitus, oral hygiene, excessive fat 
and bacterial accumulation, genetic predisposition is an 
unmodifiable factor of periodontal disease progression 
(2).
Although microbial plaque is the primary etiologic fac-
tor in periodontal disease, a subsequent study of 117 
adult twin pairs showed that 50% of susceptibility to 
periodontal disease is credited to heredity or genetic fac-
tors. In this study by Michalowicz and colleagues, mo-
nozygotic twins were more similar than dizygotic twins 
for all clinical measures and a statistically significant 
genetic variance was found for both the severity and ex-
tent of disease (3). In a population studied by Kornman 
et al. a specific interleukin-1 (IL-1) gene polymorphism 
was linked to periodontal disease. Eighty-six percent of 
the patients diagnosed with severe chronic periodontal 
disease had either the IL-1 genotype or were smokers 
(4). In a recent meta-analysis of 53 studies deduced that 
chronic periodontitis is significantly associated with 
IL-1A -889 C/T and IL-1B +3954 C/T polymorphisms, 
whereas a weak association was also detected between 
IL-1B -511 T/C and chronic periodontal disease (5).
Meta-analyses have also confirmed a positive asso-
ciation between IL-6, IL-10 gene polymorphisms and 
chronic periodontitis (6-9). IL-6 is a pleiotropic cytokine 
and its gene located in 7p15-p21 chromosome. It was 
described as a key regulator in human immune system 
that exhibits pro-inflammatory and anti-inflammatory 
roles (10,11). IL-6 levels were found to be increased in 
inflamed periodontal tissues compared to healthy (12). 
In a study with postmenopausal Japanese women, it was 
revealed that IL-6 -572 G/C polymorphism may have an 
association between periodontitis and low truncal bone 
mineral density (13). Both meta-analyses that aimed to 
clarify the association between IL-6 -572 G/C polymor-
phism and periodontal disease susceptibility revealed a 
significant increased risk of chronic periodontitis in pa-
tients with GG genotype (6,7). In the most recent meta-
analysis, the origin of the population was also investi-
gated, disclosing the high susceptibility of Europeans to 
periodontitis (7).
IL-10 is an anti-inflammatory cytokine and its gene is 
located in 1q31-32 chromosome, regulating the inflam-
matory immune response (14). This cytokine may regu-
late tissue destruction. More specifically, the progres-
sion of experimental periodontal diseases found to be 
associated with the expression of innate immune cytok-
ines: IL-10 was associated with an increased expression 
of tissue inhibitors of metalloproteinases (TIMP-1, -2 
and -3) and osteoprotegerin (OPG), and with reduced 
expression of matrix metalloproteinases (MMPs) and 
the receptor activator of nuclear factor-kappaB ligand 
(RANKL) (15). The relationship between IL-10 -592 
C/A gene polymorphism and chronic periodontitis was 
suggested by two meta-analyses (8,9). Both of them, 
that included almost the same studies, showed a signifi-
cantly higher susceptibility to periodontitis in carriers 
of the A allele. Caucasians were also recognized to have 
a significant association with this susceptible phenotype 
(8,9).
Initial periodontal treatment includes oral hygiene in-
structions and non-surgical periodontal therapy aiming 
to diminish plaque accumulation as well as gingival 
inflammation, and it is also effective in gaining attach-
ment level (16). This type of therapy has also found to 
be the best option for improving quality of life in adults 
with periodontal disease (17). The fundamental purpose 
of periodontal treatment is the long term preservation of 
natural teeth in healthy periodontal tissues. The identi-
fication of probable genetic polymorphisms associated 
with progression and development of periodontal dis-
eases may contribute in predicting the periodontal treat-
ment outcome (18).
The effects of several susceptible genotypes to chronic 
periodontitis on the outcome of non-surgical periodon-
tal treatment and tooth survival were examined in a 
meta-analysis (19). The limited number of the included 
studies as well as the lack of methodologically sound 
studies led to the conclusion that the clinical outcome 
as assessed by bleeding on probing, clinical attachment 
loss and plaque index, after non-surgical periodontal 
treatment was not associated with the genotype status 
of the patients with chronic periodontitis. In the first 
three months and in the long-term outcome, the probing 
depth was related with the genotype profile. However, 
the authors concluded that more publications are needed 
in the future to identify such associations (19).
The initial response of the host to the microbial inva-
sion is to recruit cells through the production of cy-
tokines (20). IL-6 is expressed in situations involving 
immune responses and inflammatory reactions such as 
infection and trauma by macrophages, neutrophils, ke-
ratinocytes, fibroblasts and endothelial cells (21). IL-6 
stimulates the production of antibodies and acute-phase 
proteins, activation of T- and B-cell differentiation as 
well as it induces osteoclast differentiation (22). IL-10 is 
an important anti-inflammatory cytokine with signifi-
cant immunoregulatory role. IL-10 is expressed by B- 
and T- cells, mast cells, eosinophils, macrophages and 
dendritic cells (23). Both IL-6 and IL-10 play a pivotal 
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role in the pathogenesis of periodontal disease and ele-
vated levels of these cytokines have been detected in the 
gingival crevicular fluid of periodontally inflamed tis-
sues, while both cytokine levels have been decreased in 
the gingival crevicular fluid after periodontal treatment 
(24-26). The single nucleotide polymorphism (SNPs) 
in the promoter region of IL-10 gene -592 is associated 
with altered IL-10 levels, while the carriers of the IL-6 
gene -572 C allele is related to higher levels of IL-6 than 
GG subjects in the inflammatory state (27,28).
The aim of this study was to determine the effect of IL-6 
-572 G/C (rs1800796) and IL-10 -592 C/A (rs1800872) 
polymorphisms on the outcomes of non-surgical peri-
odontal therapy (NSPT) in a Caucasian population.
Material and Methods
- Selection of participants
Patients with chronic periodontitis were recruited from 
a private practice limited to periodontics and implant 
dentistry in Thessaloniki, Greece over a period of 10 
months, between September 2014 and June 2015. The 
purpose and the procedures of the study were com-
pletely analyzed, and all patients were given a written 
consent form in accordance with the Declaration of Hel-
sinki. A total of 68 Caucasians from Greece (33 males, 
35 females, mean aged 47.53±9.62 years) were included 
in the study. The included individuals were considered 
susceptible (SCP) or non-susceptible (NSCP) to chronic 
periodontitis, according to the IL-6 (-572 G/C) and IL-
10 (-592 C/A) polymorphisms. 
- Inclusion and exclusion criteria
Complete medical history and full-mouth periodontal 
examination were obtained from all individuals. All 
participants had to be in good general health, diag-
nosed with chronic periodontitis, aged between 30 and 
70 years, with at least 16 teeth in the oral cavity. The 
participants had also to sign the consent form. The ap-
plied exclusion criteria were the following: history of 
periodontal therapy (non-surgical and surgical) within 
the past 12 months; history of severe medical disorders; 
history of systemic diseases; need for antibiotic prophy-
laxis; history of systemic antibiotic therapy in the past 3 
months; pregnant or lactating females. 
- Clinical measurements
All clinical measurements were conducted by a single, 
calibrated (weighted kappa index of agreement for pock-
et probing depths=0.88), and blinded to the genotype 
status of each patient periodontist (E.D). Probing pocket 
depth (PPD), clinical attachment loss (CAL), bleeding 
on probing (BOP), percentage of sites with PPD=4-6 
mm, percentage of sites with PPD≥7 mm, percentage of 
sites with CAL=4-6 mm, and percentage of sites with 
CAL≥7 mm were recorded utilizing a standard manual 
periodontal probe (15 UNC probe, Hu-Friedy, Chicago, 
IL, USA). All clinical periodontal parameters were as-
sessed at six sites around each tooth (mesio-buccal, mid-
buccal, disto-buccal, mesio-lingual, mid-lingual, disto-
lingual) for the whole mouth, except the third molars. 
Full-mouth measurements were obtained at baseline and 
45 days after periodontal therapy. The cementoenamel 
junction, or any other anatomical landmark in case of 
restoration, was utilized as a reference for the examina-
tion of the CAL. The presence of BOP was evaluated 15 
seconds after the periodontal probing. 
The diagnosis of chronic periodontitis was based on 
the Armitage’s classification which was adopted by 
the American Academy of Periodontology (29). In de-
tails, 30% or less of sites with periodontal destruction 
describe a localized chronic periodontitis, whereas the 
diagnosis of generalized periodontitis requires at least 
30% of sites with destruction. The severity of the dis-
ease is based on CAL: 1-2 mm (mild); 3-4 mm (moder-
ate); ≥5 mm (severe) (29). Patients were considered to 
have chronic periodontitis when exhibited the following 
periodontal measurements: two or more non-adjacent 
site demonstrated PPD≥5 mm; CAL≥3 mm; BOP.
- Periodontal therapy
All patients enrolled in the study received oral hygiene 
instruction, supragingival prophylaxis, as well as full-
mouth scaling and root planing (SRP) under local an-
esthesia. A single, calibrated, experienced and blinded 
periodontist (E.D) performed the periodontal therapy. 
Manual curettes (Hu-Friedy, Chicago, IL, USA) and 
ultrasonic instrumentation (KaVo SONOsoft LUX, 
Kavo, Germany) were utilized. Follow-up periodontal 
examination was repeated 45 days after non-surgical 
periodontal therapy by the same periodontist. 
- Blood samples, DNA separation and genotyping
Genomic DNA was extracted from blood drops using 
a commercially available genomic DNA isolation kit 
(QIAamp, DNA mini blood kit, QIAGEN, Germany) 
according to the manufacturer’s instructions. Genotyp-
ing of the polymorphisms in IL-6 -572 G/C (rs1800796) 
and IL-10 -592 C/A (rs1800872) genes was performed 
by polymerase chain reaction, in a final volume of 25 
ul with a standard protocol. The genotype of random 
samples was confirmed by sequencing analysis.
The IL-6 polymorphism genotypes were determined 
by using the 5’-GGAGACGCCTTGAAGTAACTGC-3’ 
and 5’- GAGTTTCCTCTGACTCCATCGCAG-3’ prim-
ers to generate a PCR product of 163bp that was then 
digested with BsrBI (NEB) restriction enzyme. The 
-572C allele lacks the digestion site, giving a fragment 
of 163bp, while the -572G allele gives two fragments of 
102 and 61 bp. 
Primer pair 5’-CAACTTCTTCCACCCCATCTTT-3’ 
and 5’-GTGGGCTAAATATCCTCAAAGTT-3’ was 
used to amplify a 477 bp sequence containing the IL-10 
polymorphism. Restriction enzyme RsaI (NEB) cleaved 
the -592C specific PCR product into four fragments of 
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311, 116, 42 and 8 bp and the -592A product into five 
fragments of 240, 116, 71, 42 and 8 bp.
For the IL-6 and IL-10 polymorphisms the digested 
products were separated on polyacrylamide gels stained 
with silver nitrate. 
- Groups of patients according to genotypes:
1) IL-6 group
• SCP subgroup: individuals susceptible to chronic peri-
odontitis carrying the susceptible genotype: GG (sus-
ceptible allele G).
• NSCP subgroup: individuals non-susceptible to chron-
ic periodontitis carrying the non-susceptible genotypes: 
GC or CC. 
2) IL-10 group
• SCP subgroup: individuals susceptible to chronic peri-
odontitis carrying the susceptible genotypes: CA or AA 
(susceptible allele A).
• NSCP subgroup: individuals non-susceptible to chron-
ic periodontitis carrying the non-susceptible genotype: 
CC.
3) IL-6 and IL-10 group
• SCP subgroup: individuals susceptible to chronic 
periodontitis carrying both the susceptible genotypes 
for IL-6 and IL-10: IL-6 GG and IL-10 CA or AA. 
• NSCP subgroup: individuals non-susceptible to chron-
ic periodontitis carrying one or all three non-susceptible 
genotypes: IL-6 GC, IL-6 CC, IL-10 CC. 
- Sample size calculation
The aim of the study was to assess the clinical outcome 
of the non-surgical periodontal therapy in individuals 
susceptible and non-susceptible to chronic periodon-
titis. The primary outcome variable was the PPD. A 
sample size calculation was performed before starting 
the study. A minimum difference of 1 mm in the mean 
full-mouth PPD values of each patient and a standard 
deviation (SD) of 0.5 mm was considered for the sample 
size calculation. Aiming to achieve a 95% power of the 
study, it was determined that 6 subjects per group would 
be essential. Thus, the included number of patients in 
our study (68 patients) was sufficient enough to detect 
clinical differences (PS: Power and Sample Size Calcu-
lation version 3.1.2, 2014). 
- Statistical analysis
The Shapiro-Wilk test was utilized to assess the nor-
mality of the distribution. Chi-square test and Mann-
Whitney U test were utilized to examine differences in 
SCP and NSCP patients as far as age, gender, smoking 
status, alcohol consumption and number of teeth are 
concerned. Mann-Whitney and Wilcoxon tests were 
performed to evaluate the differences of the clinical 
measurements (PPD, CAL, BOP, percentage of sites 
with 4-6 mm and ≥7 mm PPD and CAL) between the 
SCP and NSCP groups at the same (baseline or 45 days 
after therapy) and different time points respectively 
(baseline and 45 days after therapy). Multiple logistic 
regression analysis was performed to analyze the as-
sociation between the genotypes and the clinical and 
demographic variables. The Bonferroni test was also 
utilized for post-hoc analysis to adjust the results for the 
eight variables analyzed taking into consideration the 
multiple comparisons. All statistical procedures were 
performed with statistical software (SPSS v.19.0 for 
Windows, IBM, Armonk, NY, USA). Statistical signifi-
cance was set at P <0.05. 
Results
This study included 68 Caucasians with chronic peri-
odontal disease who were divided into two groups ac-
cording to the presence or absence of the susceptible 
IL-6, IL-10 genotype: SCP and NSCP. One participant 
was excluded from the study as well as from the sta-
tistical analysis because he failed to come to the re-
evaluation appointment due to change of residency. The 
final sample population of 67 Caucasians mean aged 
of 47.63 (±9.66) years was consisted of 35 (52.24%) fe-
males and 39 (58.21%) non-smokers. The IL-6 SCP and 
NSCP groups exhibited similar age and smoking his-
tory, whereas the male population showed significantly 
higher prevalence of periodontal disease susceptibility 
compared to the female population (p=0.04). In addi-
tion, the mean number of teeth of the SCP group was 
significantly higher in comparison to the NSCP group 
(p=0.01). Similar distribution was recorded in regards 
to age, gender, smoking status, alcohol consumption and 
number of teeth in the IL-10 group. The demographic 
characteristics of the study population are presented in 
Table 1.
- Non-surgical periodontal treatment outcomes and 
genotype
The influence of genetic susceptibility to chronic peri-
odontal disease in the IL-6 and IL-10 gene was evalu-
ated. We analyzed the effects of non-surgical perio-
dontal therapy on the clinical parameters between 
SCP and NSCP to chronic periodontitis, according to 
the IL-6 -572 G/C (Table 2), IL-10 -592 C/A (Table 3) 
polymorphisms as well as their combination (Table 4). 
In particular, the differences in the clinical parameters 
between the SCP and NSCP groups were compared be-
fore and after non-surgical periodontal therapy. Both 
SCP and NSCP groups demonstrated similar clinical 
parameters (PPD, CAL, BOP, percentage of sites with 
PPD=4-6 mm, percentage of sites with PPD≥7 mm, 
percentage of sites with CAL=4-6 mm, and percentage 
of sites with CAL≥7 mm) at baseline (p>0.05), while 
45 days after treatment all of them were significantly 
decreased (p<0.001). Furthermore, SCP and NSCP pa-
tients showed similar significant clinical improvements 
after periodontal treatment, but neither SCP nor NSCP 
groups revealed any significant difference in the clinical 
parameters at day 45. 
































































































































































































































































































































































































































































































































































































































































































































































































Med Oral Patol Oral Cir Bucal. 2017 Jul 1;22 (4):e446-57.                                                                                                               Treatment outcome and gene polymorphisms
e451





































Percentage of sites 












Percentage of sites 












Percentage of sites 

























Table 2. Clinical parameters (median; minimum-maximum) in chronic periodontitis patients at 
baseline and 45 days after non-surgical periodontal treatment of IL-6 susceptible (SCP) and non-
susceptible (NSCP) patients.
*Wilcoxon test: evaluation of the difference between baseline and 45 days for SCP and NSCP 
groups. The difference is significant at <0.05 level.
**Mann-Whitney test: evaluation of the difference between SCP and NSCP groups at baseline and 
45 days. The difference is significant at <0.05 level.
Abbreviations:
PPD: Probing pocket depth.
CAL: Clinical attachment loss.
BOP: Bleeding on probing.
SCP: Susceptible.
NSCP: Non-susceptible.
- Multiple logistic regression analysis 
Multiple logistic regression analysis was utilized to 
identify whether there was any association between 
the examined genotypes and the demographic char-
acteristics as well as the clinical parameters (Table 
5). At baseline, a significant association between IL-6 
-572G/C, gender (p=0.01) and number of teeth (p=0.04) 
was detected. Similarly, 45 days after periodontal ther-
apy, gender (p=0.01), number of teeth (p=0.01), prob-
ing pocket depth and clinical attachment loss (p=0.01) 
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Table 3. Clinical parameters (median; minimum-maximum) in chronic periodontitis patients at baseline and 45 days 
after non-surgical periodontal treatment of IL-10 susceptible (SCP) and non-susceptible (NSCP) patients.
*Wilcoxon test: evaluation of the difference between baseline and 45 days for SCP and NSCP groups. The difference is 
significant at <0.05 level. 
**Mann-Whitney test: evaluation of the difference between SCP and NSCP groups at baseline and 45 days. The diffe-
rence is significant at <0.05 level. 
Abbreviations:
PPD: Probing pocket depth.
CAL: Clinical attachment loss.
BOP: Bleeding on probing.
SCP: Susceptible.
NSCP: Non-susceptible.
were significantly associated with this genotype. The 
results were adjusted according to the Bonferroni cor-
rection in order to avoid potential biased results from 
multiple comparisons, and only the association between 
probing pocket depth (p=0.04), clinical attachment loss 
(p=0.04) and IL-6 -572G/C remained. IL-10 -592 C/A 
did not exhibit any association with the examined clini-
cal and demographic parameters. 
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Table 4. Clinical parameters (median; minimum-maximum) in chronic periodontitis patients at baseline and 45 days 
after non-surgical periodontal treatment of IL-6 and IL-10 susceptible (SCP) and non-susceptible (NSCP) patients.
*Wilcoxon test: evaluation of the difference between baseline and 45 days for SCP and NSCP groups. The difference 
is significant at <0.05 level.
**Mann-Whitney test: evaluation of the difference between SCP and NSCP groups at baseline and 45 days. The diffe-
rence is significant at <0.05 level.
Abbreviations:
PPD: Probing pocket depth.
CAL: Clinical attachment loss.
BOP: Bleeding on probing.
SCP: Susceptible.
NSCP: Non-susceptible.
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Table 5. Multiple logistic regression analysis for the association between the IL-6 -572 G/C and IL-10 -592 C/A genotypes and the 
demographic and clinical variables at baseline and 45 days.
The results were adjusted for the eight variables analyzed according to the Bonferroni correction in order to avoid biased results from 
multiple comparisons (p-corrected after adjustment).*p-values shown in bold indicate statistical significance (p<0.05).
PPD: Probing pocket depth; CAL: Clinical attachment loss; BOP: Bleeding on probing.
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Discussion
In this study, 67 patients of a private practice limited 
to Periodontics and Implant Dentistry were included 
and clinically examined. The effect of IL-6 -572 G/C 
and IL-10 -592 C/A polymorphisms on the non-surgical 
periodontal treatment outcome was evaluated. The hy-
pothesis was that individuals susceptible to chronic peri-
odontal disease would demonstrate decreased treatment 
response to non-surgical periodontal therapy compared 
to non-susceptible individuals. We failed to support 
our hypothesis, and all individuals showed similar sig-
nificant clinical improvement. Individuals with chronic 
periodontal disease with similar periodontal clinical pa-
rameters at baseline, showed significant improvement 
in all clinical parameters 45 days after non-surgical 
periodontal therapy. However, none of the groups (SCP 
or NSCP) demonstrated any superiority. The results of 
our study suggest that IL-6 -572 G/C and IL-10 -592 
C/A polymorphisms as well as their combination do not 
influence the periodontal treatment outcome. 
According to a meta-analysis published by our group, 
this is the first study that evaluate the association be-
tween IL-6 -572 G/C, IL-10 -592 C/A polymorphisms 
and non-surgical periodontal treatment outcome (19). 
Both polymorphisms have been shown to be associ-
ated with chronic periodontal disease, as evidenced 
by various meta-analysis (6-9). Previous publications 
that aimed to assess the effect of genotype on the peri-
odontal treatment outcome, examined polymorphisms 
of MMP-1, MMP-13, IL-1, IL-4, IL-6, IL-8 and man-
nose-binding lectin (MBL) (30-38). All studies were 
conducted in university settings and the included indi-
viduals were followed-up for 45 days to 6 months after 
non-surgical periodontal therapy. 
The results of this study are in agreement with the ma-
jority of the publications. In a similar designed study 
from Corbi et al, patients from a dental school with 
moderate and localized chronic periodontitis were ex-
amined by a single calibrated examiner before and 45 
days after treatment. No significant differences were 
observed between IL-8 ATC/TTC haplotype and peri-
odontal treatment outcome and the authors concluded 
that studies with patients from different ethnicities and 
diagnosed with generalized severe chronic periodontitis 
were necessary (36). In our study, European Caucasian 
patients from Greece with significantly more severe 
periodontal disease were included. 
Similar studies demonstrated no significant differences 
between genetic polymorphisms and response to non-
surgical periodontal therapy for MMP-13, IL-1, IL-4, 
and MBL (30-33,35,38). Pirhan and colleagues aimed to 
examine the effect of MMP-1 (-519 A/G; -1607 1G/2G) 
in a Turkish population with chronic periodontitis. Six 
months after periodontal therapy, the investigators re-
ported that 519G allele carried higher percentage of 
sites with 4-6 mm clinical attachment loss after treat-
ment. However, their finding did not show a clear rela-
tion to the progression of the disease, but further stud-
ies with different ethnic populations and larger samples 
were needed (34). In a prospective longitudinal study, 
D’ Aiuto et al. included 94 patients with generalized 
severe periodontitis and aimed to assess the relative 
contribution of several factors such as smoking, IL-6 
polymorphisms, tooth mobility, tooth type and location 
on the treatment outcome after non surgical periodon-
tal therapy. Six months after periodontal treatment, the 
authors detected a significant smaller decrease in the 
number of pockets in susceptible patients compared to 
non-susceptible ones (37).
IL-6 -572 G/C polymorphisms lead to an increase in the 
expression of IL-6, which plays a key role in the sus-
ceptibility to periodontal disease. The promoter region 
of the IL-6 controls the IL-6 transcription through a 
complex pathway, which is regulated by these polymor-
phisms (39). Similarly, IL-10 -592 C/A polymorphisms 
have been associated with an increased production of 
IL-10 protein, which is related with increased inflam-
matory response (9). However, our study did not detect 
any significant association between susceptible geno-
types to periodontal disease and periodontal treatment 
outcome. The lack of association could be explained 
by other patient-related factors, which may impact 
significantly the outcome of non-surgical periodontal 
therapy. Poor compliance with oral hygiene and erratic 
compliance to maintenance are factors influencing the 
treatment outcome (40,41). Moreover, it is possible that 
combination of polymorphisms in more than two genes 
can have an effect on periodontal treatment outcomes. 
In our study, the short-term evaluation period and the 
demonstration of oral hygiene before the onset of ther-
apy aimed to minimize these risk factors. Additionally, 
the presence of systemic conditions such as diabetes 
mellitus and smoking have also been shown to exhibit 
significant effect on periodontal healing after non-sur-
gical therapy (42,43). For these reasons, individuals in 
good general health were only included in this study, 
while smokers were equally distributed among SCP and 
NSCP patients. In regards to the type of therapy, non-
surgical periodontal therapy was provided and no surgi-
cal treatment or anti-infective therapy was performed in 
order to eliminate any possible effect on the treatment 
outcome.
The lack of socioeconomic information for the partici-
pants is one of the limitations of the study. However, 
the significant majority of the individuals treated in this 
private practice limited to Periodontics and Implant 
Dentistry were Greeks of middle class. Another limi-
tation of the present study is the short-term follow-up. 
Although the participants of this study were clinically 
re-examined only 45 days after periodontal treatment, 
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the study duration did not differ significantly from 
similar studies in the literature. The follow-up period of 
analogous studies ranged from 1 to 3 months. One of the 
strengths of this study is the big sample of a private prac-
tice population treated by a single periodontist leading to 
less operator bias. The sample size of this study was suf-
ficient enough to detect clinical differences according to 
the sample size calculation which showed that 6 patients 
per group are essential to achieve a 95% power. The final 
size of the study population, 67 individuals, was able to 
reveal any potential association between the investigated 
genotypes and the treatment outcome.
Future studies are required to examine the potential as-
sociation of different genetic polymorphisms of various 
genes with the response of the non-surgical periodontal 
therapy. Moreover, due to the multifactorial role of peri-
odontal diseases, additional studies that will take into 
account a wide range of confounding factors such as 
smoking, ethnicities, races, bacterial strains and medi-
cal conditions are indicated. In the future we would like 
also to look into parameters that can have an epigenetic 
effect on polymorphisms. It is possible that different 
periopathogens or smoking or increased glycocylated 
hemoglobin can alter the genome and make the peri-
odontal patient more susceptible to periodontal disease. 
Moreover, we can also make the hypothesis that smok-
ing cessation or good oral hygiene or good glycemic 
control can have a beneficial epigenetic effect as far as 
the periodontal disease (44).
The analysis in the present study shows that after 
NSPT, genetic susceptibility to chronic periodontitis in 
the IL-6 and IL-10 genes did not affect the periodontal 
treatment outcome. IL-6 and IL-10 genes have both a 
significant effect on the initiation of periodontal disease 
and increased levels of these proteins have been found 
in the gingival crevicular fluid of sites with periodontal 
destruction (24,25). Following periodontal treatment, 
gingival crevicular fluid and serum IL-6 and IL-10 
levels have been decreased or remained stable reveal-
ing that the resolution of the tissue inflammation and 
periodontal destruction is unlikely to significantly in-
fluence these protein levels (25,26,45-47). Moreover, 
it is possible that the expression of IL-6 and IL-10 can 
alter the levels of other cytokines or inflammatory fac-
tors that play a significant role only in the initiation of 
the inflammatory response and not in the healing pro-
cess after treatment of periodontal disease. Although 
the association between IL-6 and IL-10 with periodon-
tal disease initiation has been supported extensively 
in the literature, the findings of this study can confirm 
the lack of effect of IL-6 and IL-10 on the resolution of 
periodontal inflammation. In addition, albeit increased 
IL-10 levels have been associated with the presence of 
the SNP polymorphism in the promoter region of IL10 
gene -592, this study fails to show a significant associa-
tion between the presence of the polymorphism and the 
periodontal treatment outcome. This comes in agree-
ment with previous data supporting the predominant 
anti-inflammatory role of this protein (14). However, no 
investigation was performed in the IL-10 protein lev-
els that would shed some light in the association of the 
treatment outcome with the protein levels. 
Although abundant evidence does support an associa-
tion between IL-6 and IL-10 genes polymorphisms with 
susceptibility to chronic periodontitis, we observed that 
NSPT was not influenced by the susceptible genotypes. 
Treatment was equally effective for all studied param-
eters (probing depth, attachment loss, bleeding on prob-
ing, percentage of sites with 4-6 mm and ≥7 mm pocket 
depth and attachment loss). Further studies that will 
take into account a wide range of confounding factors 
such as smoking, ethnicities, bacterial strains and medi-
cal conditions are required to determine the potential 
association of different genetic polymorphisms of vari-
ous genes with the response of the non-surgical peri-
odontal therapy.
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